Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients-Reference-Cited by-同舟云学术

Ruxolitinib Combined with Corticosteroids as First-Line Therapy for Acute Graft-versus-Host Disease in Haploidentical Peripheral Blood Stem Cell Transplantation Recipients

Published:2021-01 Issue:1 Volume:27 Page:75.e1-75.e10
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Hou Cheng,Dou Liping,Jia Mingyu,Li Fei,Wang Shuhong,Gao Xiaoning,Wang Lu,Jin Xiangshu,Wang Lijun,Gao Chunji,Liu Daihong

Funder

Beijing Municipal Natural Science Foundation

National Natural Science Foundation of China

Beijing Nova Program

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference35 articles.

1. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis;Ruutu;Bone Marrow Transplant,2017

2. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia;Yeshurun;Blood Adv,2019

3. Efficacy and safety of unmanipulated haploidentical related donor allogeneic peripheral blood stem cell transplantation in patients with relapsed/refractory acute myeloid leukemia;Dou;Chin Med J (Engl),2018

4. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey;Zeiser;Leukemia,2015

5. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib on acute graft-versus-host disease prophylaxis after modified donor lymphocyte infusion;Transplant Immunology;2023-02

2. Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II controlled trial;Trials;2022-06-06

3. Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies;Drug Design, Development and Therapy;2022-03

4. Elevated REG3α predicts refractory aGVHD in patients who received steroids-ruxolitinib as first-line therapy;Annals of Hematology;2021-11-23

5. Janus Kinase Inhibitors and Cell Therapy;Frontiers in Immunology;2021-08-31